Chiesi USA, Inc.
Chiesi USA is a subsidiary of the international biopharmaceutical group Chiesi Group, headquartered in Parma, Italy. The company is committed to developing and commercializing innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. With a focus on sustainability, innovation, and social responsibility, Chiesi USA aims to improve patients' quality of life through its diverse product portfolio and research initiatives. The company operates in a global context with a strong emphasis on R&D, sustainability, and corporate compliance.
Industries
Nr. of Employees
Very Large (1000+)
Chiesi USA, Inc.
175 Regency Woods Place, Suite 600, Cary, NC 27518
Patents
Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
US-8455524-B2
View Details
Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
US-8455524-B2
View DetailsProducts
Intravenous short‑acting dihydropyridine formulation (clevidipine injectable emulsion)
An intravenous emulsion formulation of a short-acting dihydropyridine vasodilator indicated for acute blood pressure control in hospital settings.
Nebulized/inhalation antibiotic solution (tobramycin inhalation solution)
An inhaled antibiotic solution formulated for nebulization to deliver antimicrobial therapy directly to the respiratory tract.
Oral iron‑chelating therapy for transfusional iron overload (deferiprone)
An oral small-molecule iron chelator indicated to reduce transfusional iron overload in patients with thalassemia syndromes, sickle cell disease and other anemias, with associated monitoring and safety guidance.
Respiratory therapeutic portfolio (inhaled and hospital respiratory products)
Commercial and late-stage inhaled therapies and hospital-directed respiratory products for treatment of asthma, COPD and pulmonary infections, including programs addressing lower global warming potential propellants.
Rare disease therapeutics and enzyme replacement approaches
Development, regulatory filing and commercialization of therapies for rare and ultra-rare disorders, including enzyme replacement programs and integrated acquired product portfolios.
Biotech manufacturing capacity and center of excellence
Planned and operational investments to provide biologics production and process development capabilities to support clinical and commercial supply needs.
Intravenous short‑acting dihydropyridine formulation (clevidipine injectable emulsion)
An intravenous emulsion formulation of a short-acting dihydropyridine vasodilator indicated for acute blood pressure control in hospital settings.
Nebulized/inhalation antibiotic solution (tobramycin inhalation solution)
An inhaled antibiotic solution formulated for nebulization to deliver antimicrobial therapy directly to the respiratory tract.
Oral iron‑chelating therapy for transfusional iron overload (deferiprone)
An oral small-molecule iron chelator indicated to reduce transfusional iron overload in patients with thalassemia syndromes, sickle cell disease and other anemias, with associated monitoring and safety guidance.
Respiratory therapeutic portfolio (inhaled and hospital respiratory products)
Commercial and late-stage inhaled therapies and hospital-directed respiratory products for treatment of asthma, COPD and pulmonary infections, including programs addressing lower global warming potential propellants.
Rare disease therapeutics and enzyme replacement approaches
Development, regulatory filing and commercialization of therapies for rare and ultra-rare disorders, including enzyme replacement programs and integrated acquired product portfolios.
Biotech manufacturing capacity and center of excellence
Planned and operational investments to provide biologics production and process development capabilities to support clinical and commercial supply needs.
Services
Case-by-case provision of investigational products outside clinical trials for eligible patients; treating physicians submit requests via an online portal and Medical Affairs evaluates eligibility and safety considerations.
Corporate compliance framework covering marketing and sales conduct, confidential reporting channels and annual collection and submission of Open Payments data with guidance on dispute processes.
Patient-facing support channels, copay assistance options and collaborations with patient advocacy organizations for rare diseases and specialty care communities.
Review and evaluation of non-confidential acquisition or licensing opportunities, focusing on assets that have completed Phase II in rare disease, hospital or adjacent specialty markets.
Funding program supporting independent medical education, healthcare-related charitable projects, scientific research and medical fellowships in the United States.
Case-by-case provision of investigational products outside clinical trials for eligible patients; treating physicians submit requests via an online portal and Medical Affairs evaluates eligibility and safety considerations.
Corporate compliance framework covering marketing and sales conduct, confidential reporting channels and annual collection and submission of Open Payments data with guidance on dispute processes.
Patient-facing support channels, copay assistance options and collaborations with patient advocacy organizations for rare diseases and specialty care communities.
Review and evaluation of non-confidential acquisition or licensing opportunities, focusing on assets that have completed Phase II in rare disease, hospital or adjacent specialty markets.
Funding program supporting independent medical education, healthcare-related charitable projects, scientific research and medical fellowships in the United States.
Expertise Areas
- Clinical trial management for late-stage studies
- Biologics development and bioprocessing scale-up
- Rare and ultra-rare disease therapeutics
- Hospital and acute-care product commercialization
Key Technologies
- Phase II/III clinical trial methodologies
- GMP-compliant biologics manufacturing
- Intravenous emulsion formulation
- Nebulized/inhalation formulation technologies
News & Updates
Chiesi Group reports strong financial results for 2024, with revenues of €3.4 billion and a 13% increase at CER.
Bioasis Technologies and Chiesi Group enter into a licensing agreement for the xB3 platform targeting lysosomal storage disorders.
Best Place to Work 2018
Chiesi USA recognized as one of the best workplaces by Triangle Business Journal.
B Corp Certification
Chiesi USA is a certified B Corporation, demonstrating high social and environmental performance.
Top Employer USA 2025
Recognized as a top employer in the United States for 2025.
Life Science Award 2021
Chiesi USA awarded by Triangle Business Journal for excellence in life sciences.
Chiesi Group reports strong financial results for 2024, with revenues of €3.4 billion and a 13% increase at CER.
Bioasis Technologies and Chiesi Group enter into a licensing agreement for the xB3 platform targeting lysosomal storage disorders.
Best Place to Work 2018
Chiesi USA recognized as one of the best workplaces by Triangle Business Journal.
B Corp Certification
Chiesi USA is a certified B Corporation, demonstrating high social and environmental performance.
Top Employer USA 2025
Recognized as a top employer in the United States for 2025.
Life Science Award 2021
Chiesi USA awarded by Triangle Business Journal for excellence in life sciences.